[go: up one dir, main page]

MXPA04005003A - Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo. - Google Patents

Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo.

Info

Publication number
MXPA04005003A
MXPA04005003A MXPA04005003A MXPA04005003A MXPA04005003A MX PA04005003 A MXPA04005003 A MX PA04005003A MX PA04005003 A MXPA04005003 A MX PA04005003A MX PA04005003 A MXPA04005003 A MX PA04005003A MX PA04005003 A MXPA04005003 A MX PA04005003A
Authority
MX
Mexico
Prior art keywords
composition
potentiating
endothelin antagonists
opiate analgesic
ina method
Prior art date
Application number
MXPA04005003A
Other languages
English (en)
Inventor
Anil Gulati
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MXPA04005003A publication Critical patent/MXPA04005003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composicion y metodos para tratarel dolor y para reducir o revertir la tolerancia a los analgesicos. La composicion y metodo utilizan un analgesico opiaceo y un antagonista de endotelina como agentes activos para tratar el dolor en mamiferos, incluyendo humanos.
MXPA04005003A 2001-11-27 2002-11-22 Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo. MXPA04005003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33359901P 2001-11-27 2001-11-27
PCT/US2002/037461 WO2003045434A2 (en) 2001-11-27 2002-11-22 Endothelin antagonists ina method and composition for potentiating an opiate analgesic

Publications (1)

Publication Number Publication Date
MXPA04005003A true MXPA04005003A (es) 2004-08-11

Family

ID=23303472

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005003A MXPA04005003A (es) 2001-11-27 2002-11-22 Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo.

Country Status (14)

Country Link
US (3) US7973064B2 (es)
EP (1) EP1448233A2 (es)
JP (1) JP2005513033A (es)
CN (1) CN1646166A (es)
AU (1) AU2002348224A1 (es)
BR (1) BR0214481A (es)
CA (1) CA2464768C (es)
CO (1) CO5590940A2 (es)
EA (1) EA200400734A1 (es)
EC (1) ECSP045153A (es)
MX (1) MXPA04005003A (es)
NO (1) NO20042612L (es)
WO (1) WO2003045434A2 (es)
ZA (1) ZA200403162B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569238A (zh) * 2019-09-30 2021-03-30 武汉大学 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070300258A1 (en) * 2001-01-29 2007-12-27 O'connor Daniel Methods and systems for providing media assets over a network
DK2266558T3 (en) * 2001-06-07 2017-07-31 Analgesic Neuropharmaceuticals Llc TREATMENT OF NEUROPATHIC PAIN WITH RECEPTOR ANTAGONIST: N-METHYL-D-ASPARTATE (NMDA)
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
ATE455545T1 (de) 2001-11-01 2010-02-15 Spectrum Pharmaceuticals Inc Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20040138121A1 (en) 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2007030770A2 (en) * 2005-09-09 2007-03-15 Chicago Labs, Inc. Endothelin receptors in morphine withdrawal
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
RU2009111605A (ru) 2006-08-31 2010-10-10 Спектрум Фармасьютикалз, Инк. (Us) Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
US20090143426A1 (en) * 2007-12-04 2009-06-04 Ralph Anthony Stephani Synthesis of 1,3,6-trisubstituted-2-carboxyquinol-4-ones as selective ET A antagonists and their use as medicaments
CN103989682B (zh) 2009-04-30 2016-03-30 美国中西部大学 使用centhaquin的治疗法
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
CN105682741A (zh) 2013-07-08 2016-06-15 美国中西部大学 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法
CN114796448A (zh) * 2022-05-06 2022-07-29 延安大学 可乐定与Gap26在制备镇痛药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
JPH08139146A (ja) 1994-11-14 1996-05-31 Shin Etsu Handotai Co Ltd 半導体表面のライフタイム評価方法
ES2244966T3 (es) 1994-12-12 2005-12-16 Omeros Corporation Solucion de irrigacion y su utilizacion para inhibir perioperatoriamente el dolor, la inflamacion y el espasmo en una herida.
US6673832B1 (en) * 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
MXPA02010764A (es) 2000-05-31 2003-03-10 Warner Lambert Co Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico.
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) * 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569238A (zh) * 2019-09-30 2021-03-30 武汉大学 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用

Also Published As

Publication number Publication date
WO2003045434A3 (en) 2003-09-25
CN1646166A (zh) 2005-07-27
JP2005513033A (ja) 2005-05-12
US20030100507A1 (en) 2003-05-29
US20100311665A1 (en) 2010-12-09
ZA200403162B (en) 2005-01-26
CA2464768C (en) 2009-12-29
NO20042612L (no) 2004-06-22
WO2003045434A2 (en) 2003-06-05
BR0214481A (pt) 2004-09-14
US20100113396A1 (en) 2010-05-06
US8114896B2 (en) 2012-02-14
EP1448233A2 (en) 2004-08-25
ECSP045153A (es) 2004-08-27
US7973064B2 (en) 2011-07-05
US8410148B2 (en) 2013-04-02
CA2464768A1 (en) 2003-06-05
AU2002348224A1 (en) 2003-06-10
EA200400734A1 (ru) 2004-12-30
CO5590940A2 (es) 2005-12-30

Similar Documents

Publication Publication Date Title
MXPA04005003A (es) Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo.
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2005107726A3 (en) Method for the treatment of back pain
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
WO2005000215A3 (en) Methods for treating pain
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
MY169308A (en) Treatment of tnf? related disorders
IL149890A0 (en) Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
BRPI0509420A (pt) método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico
WO2004071413A3 (en) Method and composition for potentiating an opiate analgesic
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
EP1178796A4 (en) AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
PL342063A1 (en) Treatment of papular lymphomas using inhibitors of lymphotoxin path
WO2002039996A3 (en) Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
BR0111785A (pt) Composições e métodos para tratamento de candidìase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal